Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14456975 | 0.89 | CNR1 (0.60) | CNR1ALDH1A1LMNATSHRPOLB | |
| SCHEMBL14456964 | 0.81 | CNR1 (0.60) | CNR1ALDH1A1LMNATSHRPOLB | |
| SCHEMBL14456977 | 0.81 | POLB (0.56) | CNR1ALDH1A1LMNATSHRPOLB | |
| SCHEMBL14456956 | 0.79 | CNR1 (0.69) | CNR1ALDH1A1LMNATSHRPOLB | |
| SCHEMBL14456976 | 0.79 | POLB (0.52) | CNR1ALDH1A1LMNATSHRPOLB | |
| SCHEMBL14457004 | 0.78 | ALDH1A1 (0.54) | ALDH1A1LMNATSHRPOLBKMT2A | |
| SCHEMBL8230868 | 0.78 | ACKR3 (0.46) | — | |
| SCHEMBL4275882 | 0.77 | CNR1 (1.00) | CNR1ALDH1A1LMNANPSR1 | |
| SCHEMBL14456952 | 0.76 | POLB (0.78) | ALDH1A1LMNATSHRPOLBKMT2A | |
| SCHEMBL14456989 | 0.76 | POLB (0.49) | ALDH1A1LMNATSHRPOLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | CNR1 4/4885ALDH1A1 3184/4885LMNA 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.